Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
Status:
Available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an open label expanded access protocol for the treatment of up to approximately 40
adult or pediatric (defined as age <18 years) patients with tumors harboring either a
chromosomal translocation or activating mutation involving the ALK or ROS1 gene or an
activating genetic alteration involving the cMET gene who cannot swallow the crizotinib
capsule but may be able to derive benefit from treatment with an alternative oral formulation
of crizotinib.